NCT04814407 Developing Novel Circulating Epigenetic Biomarkers for Early Detection of Lung Cancer
| NCT ID | NCT04814407 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Taiwan University Hospital |
| Condition | Lung Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 900 participants |
| Start Date | 2021-03-01 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 900 participants in total. It began in 2021-03-01 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The investigators aim to identify novel circulating methylated biomarkers for early lung cancer detection as well as to develop new technologies that are clinically applicable with high sensitivity and specificity.
Eligibility Criteria
Inclusion Criteria: * Subjects suspected or confirmed diagnosis of lung cancer. * Subjects who had indeterminate sub-centimeter pulmonary nodules or ground glass opacities discovered by computed tomography. * Non-cancer subjects: including healthy volunteers and chronic inflammatory airway diseases such as chronic obstructive airway disease, asthma, and bronchiectasis, etc. * Subjects age over 20. Exclusion Criteria: * Pregnancy. * Subjects with HIV infection. * Unable to or unwilling to give informed consent.
Contact & Investigator
Hsing-Chen Tsai, M.D., Ph.D
STUDY CHAIR
Graduate institute of Toxicology, NTUCM; Department of Internal Medicine, NTUH
Frequently Asked Questions
Who can join the NCT04814407 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, studying Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04814407 currently recruiting?
Yes, NCT04814407 is actively recruiting participants. Contact the research team at htsai@ntu.edu.tw for enrollment information.
Where is the NCT04814407 trial being conducted?
This trial is being conducted at Taipei, Taiwan.
Who is sponsoring the NCT04814407 clinical trial?
NCT04814407 is sponsored by National Taiwan University Hospital. The principal investigator is Hsing-Chen Tsai, M.D., Ph.D at Graduate institute of Toxicology, NTUCM; Department of Internal Medicine, NTUH. The trial plans to enroll 900 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.